These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 347574)
1. Schizophrenic symptoms improve with apomorphine. Tamminga CA; Schaffer MH; Smith RC; Davis JM Science; 1978 May; 200(4341):567-8. PubMed ID: 347574 [TBL] [Abstract][Full Text] [Related]
2. Effect of apomorphine on schizophrenic symptoms. Smith RC; Tamminga C; Davis JM J Neural Transm; 1977; 40(2):171-6. PubMed ID: 323423 [TBL] [Abstract][Full Text] [Related]
3. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737 [TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics. Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291 [TBL] [Abstract][Full Text] [Related]
9. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? Dépatie L; Lal S J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190 [TBL] [Abstract][Full Text] [Related]
10. Apomorphine reduces schizophrenic symptoms. Schaffer MH; Tamminga CA; Smith RC; Davis JM Psychopharmacol Bull; 1980 Jan; 16(1):55-7. PubMed ID: 6987694 [No Abstract] [Full Text] [Related]
11. Apomorphine as a preferential stimulant of self-inhibitory dopamine receptors in man. Corsini GU; Del Zompo M; Piccardi MP; Mangoni A; Gessa GL Ann Ist Super Sanita; 1978; 14(1):123-30. PubMed ID: 756167 [TBL] [Abstract][Full Text] [Related]
12. Effects of dopamine agonists and antagonists in Tourette's disease. Feinberg M; Carroll BJ Arch Gen Psychiatry; 1979 Aug; 36(9):979-85. PubMed ID: 380492 [TBL] [Abstract][Full Text] [Related]
14. Dopaminergic function in two patients with catalepsy. Cervantes P; Lal S; Smith F; Guyda H Acta Psychiatr Scand; 1977 Mar; 55(3):214-9. PubMed ID: 848340 [TBL] [Abstract][Full Text] [Related]
15. A demonstration of the ability of apomorphine to act on dopamine receptors on nerve terminals in the nucleus accumbens to reduce locomotor hyperactivity [proceedings]. Costall B; Hui SC; Naylor RJ Br J Pharmacol; 1979 Nov; 67(3):475P-476P. PubMed ID: 497587 [No Abstract] [Full Text] [Related]
16. Midification of tardive dyskinesia and spasmodic torticollis by apomorphine. Possible role of dopamine autoreceptors. Tolosa ES Arch Neurol; 1978 Jul; 35(7):459-62. PubMed ID: 666598 [TBL] [Abstract][Full Text] [Related]
17. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808 [TBL] [Abstract][Full Text] [Related]
18. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
19. Apomorphine's antipsychotic activity. Schaffer MH; Davis JM; Tamminga CA Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035 [No Abstract] [Full Text] [Related]
20. Apomorphine and psychopathology. Lal S; De la Vega CE J Neurol Neurosurg Psychiatry; 1975 Jul; 38(7):722-6. PubMed ID: 1099172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]